<DOC>
	<DOCNO>NCT00125138</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy three target dose melperone compare placebo treatment psychosis associate Parkinson 's disease . Subjects enrol approximately 20 investigational site United States ( U.S. ) 15 Ex-US site . The maximum study duration 10 week . Subjects option continue open-label extension study .</brief_summary>
	<brief_title>Melperone ( Anti-Psychotic ) Patients With Psychosis Associated With Parkinson 's Disease</brief_title>
	<detailed_description>Parkinson 's Disease progressive neurodegenerative disorder characterize bradykinesia , rigidity , tremor abnormal posture gait . Many patient mild moderate symptom , others advance disease symptom interfere activity daily live severe degree . Although effective address motor dysfunction , long-term use anti-Parkinsonian agent implicated component development psychiatric side effect include psychosis . Treatment psychosis typical antipsychotic recommend patient population , since even low potency typical antipsychotic cause mark exacerbation parkinsonism Parkinson 's disease patient . The use atypical antipsychotic ( e.g. , clozapine , risperidone quetiapine ) show efficacy treatment psychosis PD patient . Melperone classify atypical antipsychotic . European experience melperone span 30 year , encompass establish antipsychotic efficacy profile treatment confusion , anxiety , unrest ( particularly elderly ) schizophrenia well favorable safety tolerability profile . Eligible subject Parkinson 's disease psychosis participate 1-2 week Screening/Washout Period , 5 week Titration Phase ( one three dose melperone placebo ) , 1 week Maintenance Phase Taper/Follow-up Period 2 week . Following Day 43 assessment , subject may give option receive melperone open-label extension study .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Metylperon</mesh_term>
	<criteria>The subject subject 's legally authorize representative ( LAR ) must sign date IRB/IEC approve Informed Consent Form HIPAA Authorization ( applicable US site ) prior study participation . Male female subject . If female : Subject either childbearing potential , defined postmenopausal least 1 year surgically sterile ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) , childbearing potential , must comply method birth control acceptable investigator study , least one month prior randomization one month follow completion study . Subject breastfeed Subjects childbearing potential must negative serum pregnancy test screen visit Day 1 . Subjects clinical diagnosis idiopathic Parkinson 's Disease , define presence least three follow cardinal feature , absence alternative explanation atypical feature : Rest tremor Rigidity Bradykinesia and/or akinesia Postural gait abnormality Subjects psychosis : Presence visual and/or auditory hallucination , without delusion , occur four week prior screen visit . Symptoms severe enough clinically warrant treatment antipsychotic agent . A Hallucinations Delusions total item score ( frequency x severity ) &gt; 4 Neuropsychiatric Inventory ( NPI ) . Subjects currently treat antipsychotic agent visual and/or auditory hallucination , without delusion , four week prior screen , and/or Hallucinations Delusions total item score &lt; 4 NPI screen visit may wash ( 7 day 5 halflives , whichever longer ) return repeat screen visit . The NPI Hallucinations Delusions total item score must ≥4 repeat visit consider study entry . Subject stable dose antiParkinsonian medication ( ) least 7 day 5 halflives , whichever longer , prior screen visit expect remain stable dose duration study . Subject willing able comply study procedure . Subject systemic factor contribute psychosis urinary infection , liver disease , renal failure , anemia , infection cancer . Subject history significant psychotic disorder prior diagnosis Parkinson 's Disease , include limited schizophrenia bipolar disorder . Subject Dementia Lewybodies ( DLB ) . Subject dementia major depressive disorder preclude accurate assessment rating scale . Subject acute depressive episode time screen visit . A score MiniMental State Examination ( MMSE ) &lt; 21 . Subject dose adjustment antidepressant medication within 30 day prior screen visit , dose adjustment plan duration trial . Subject dose adjustment anxiolytic , cognitive enhancer , psychotropic medication ( exclude antipsychotic ) within 30 day prior screen dose adjustment plan duration trial . Subject receive depot antipsychotic agent within past 3 month . Subject previously fail treatment clozaril psychosis Parkinson 's disease . Subjects discontinue clozaril due intolerability may enrol . Subject use investigational product within 30 day 5 halflives , whichever longer , prior screen . Subject tolerate washout antipsychotic medication prior randomization . Subject history serious respiratory , gastrointestinal , renal , hematologic medical disorder . Subject history serious cardiovascular condition ( include , limited , Class IV angina Class IV heart failure ) and/or history risk factor Torsade de pointes ( Tdp ) ( include limit current treatment hypokalemia family history long QT syndrome ) . Subject myocardial infarction within 6 month prior screen . Subject screen ECG correct QT interval Bazett 's correction formula ( QTcB ) great 450 msec , female , 430 msec , male . Subject require treatment αagonist agent . Subject uncontrolled seizure , uncontrolled angina , uncontrolled symptomatic orthostatic hypotension ( orthostatic hypotension lead history fall 3 month prior screen ) , medical disorder would make subject poor candidate clinical trial . Subject history severe adverse reaction antipsychotic medication and/or quinine . Subject clinically significant abnormal laboratory value , ECG , find physical exam . Subject recent history current evidence substance dependence abuse . Subject unable ingest liquid medication . Subject currently treat Deep Brain Stimulation ( DBS ) . Randomization Criteria Subject Hallucinations Delusions total item score ( frequency x severity ) &gt; 4 NPI . Female subject childbearing potential must negative serum pregnancy test . Subject remain stable dose antiParkinsonian medication . Subject dose adjustment antidepressant medication since screen visit . Subjects wash previous antipsychotic agent 5 halflives 7 day , whichever long , last dose medication . Subject dose adjustment anxiolytic , cognitive enhancer psychotropic medication ( exclude antipsychotic ) since Screening Visit .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>